Abstract
In 19 patients with major depressive disorder, effective treatment with selective serotonin reuptake inhibitors (SSRIs) or amesergide (AMSG) was associated with increased cerebral perfusion in anterior cingulate cortex (SSRI and AMSG) and in medial prefrontal cortex (AMSG). Both selective serotonin reuptake inhibitors and AMSG exert antidepressant action through the serotonin (5-HT) system as reuptake inhibitors. Amesergide differs from SSRIs in that it is also a highly selective 5-HT antagonist, which may in part account for differences in cerebral blood flow response to treatment.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Brain / diagnostic imaging
-
Brain / drug effects*
-
Brain / physiopathology
-
Brain Mapping
-
Case-Control Studies
-
Chi-Square Distribution
-
Depressive Disorder, Major / drug therapy*
-
Depressive Disorder, Major / physiopathology
-
Ergolines / therapeutic use*
-
Female
-
Humans
-
Magnetic Resonance Imaging / methods
-
Male
-
Middle Aged
-
Regional Blood Flow / drug effects*
-
Regional Blood Flow / physiology
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Severity of Illness Index
-
Tomography, Emission-Computed, Single-Photon / methods
Substances
-
Ergolines
-
Serotonin Uptake Inhibitors
-
amesergide